OPTICAL IMAGING OF TUMOR ANGIOGENESIS AND CHEMOTHERAPY

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 调制成像（MI）是一种最新的技术，它使用图案化的照明和非接触式检测，以获得定量的组织光学特性在一个广泛的视野的表面下的图像。MI非常适合于癌症动物模型的非侵入性研究，可用于了解组织光学特性与组织组织学和生物化学之间的关系。特别是，我们感兴趣的肿瘤血管生成的生物学机制和化疗的改变。 研究了两种不同的动物模型。在第一个模型中，将13762个MAT-III大鼠乳腺肿瘤细胞接种到雌性Fisher 344大鼠（约160 g）的乳腺脂肪垫中。MI仪器在肿瘤生长和治疗（环磷酰胺）阶段采集组织光学特性图像。根据这些图像，对氧合血红蛋白、脱氧血红蛋白和水的组织浓度进行定量。 还测定了组织散射参数。在第二个模型中，我们在顺铂治疗（每天5 mg/kg，持续一周）下对p53/brca 1突变的转基因小鼠肿瘤进行成像。在MI测量过程中，高氧气体干预也被应用作为对比，以检测肿瘤和监测化疗效果。 到目前为止，这些研究都是非常初步的，从MI中获得的结果需要通过免疫组织化学分析来证实。然而，我们从这些动物模型的结果中发现了巨大的潜力，可以应用于临床病例。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Modulated imaging (MI) is a recent technology that uses patterned illumination and non-contact detection to obtain quantitative subsurface images of tissue optical properties over a wide field-of-view. MI is well-suited for the non-invasive study of cancer animal models that can be used to understand the relationship between tissue optical properties and tissue histology and biochemistry. In particular, we are interested in the biological mechanisms of tumor angiogenesis and their alterations from chemotherapy. Two different animal models were studied. In the first model, 13762 MAT-III rat mammary tumor cells were inoculated in the mammary fat pad of female Fisher 344 rats (~160g). The MI instrument acquired tissue optical property images during both tumor growth and treatment (Cyclophosphamide) phases. From these images, the tissue concentrations of oxy-hemoglobin, doexy-hemoglobin, and water were quantified. Tissue scattering parameters were also determined. In a second model we imaged p53/brca1 mutated transgenic mouse tumors under cisplatin treatment (5mg/kg daily for a week). During the MI measurements, hyperoxic gas intervention was also applied as a contrast to detect tumors and to monitor chemotherapeutic effects. These studies are so far very preliminary and the results obtained from MI need to be confirmed by immunohistochemical analysis. However, we have found great potential from the results of these animal models that can be applied to clinical cases.